What are the recommendations for a Muslim patient with type 2 diabetes or obesity taking Semaglutide (glucagon-like peptide-1 receptor agonist) who wishes to fast during Ramadan?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 18, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Semaglutide During Ramadan Fasting

Semaglutide should be continued during Ramadan fasting at the same dose and timing with no adjustment needed, as GLP-1 receptor agonists are safe, effective, and carry minimal hypoglycemia risk while providing excellent glucose control. 1, 2

Pre-Ramadan Preparation (6-8 Weeks Before)

Risk stratification and counseling must begin 6-8 weeks before Ramadan starts. 1 This assessment should include:

  • Evaluating glycemic control, renal function, hepatic status, and complete biochemical profile 1
  • Screening for absolute contraindications to fasting (acute coronary syndrome, advanced heart failure, severe aortic stenosis, poorly controlled arrhythmias, or recent cardiac procedures) 2
  • Confirming adequate hydration capacity during non-fasting hours 2

Patients on semaglutide alone fall into the low-risk category for fasting complications. 2 This is a critical distinction from older diabetes medications that carry substantial hypoglycemia risk.

Semaglutide Dosing During Ramadan

The dose and timing of semaglutide remain completely unchanged during Ramadan. 1 GLP-1 receptor agonists like semaglutide are designed to improve glycemic control while minimizing hypoglycemia risk, making them ideal for Ramadan fasting. 1, 2

  • Continue weekly semaglutide injections on the same schedule as before Ramadan 1
  • No dose reduction is necessary 1, 2
  • The glucose-dependent mechanism of action provides inherent safety during fasting periods 2

Managing Combination Therapy

If semaglutide is combined with other diabetes medications, adjustments are necessary:

With Metformin

Adjust metformin timing to two-thirds of total daily dose immediately before sunset meal (Iftar) and one-third before predawn meal (Suhur). 1, 2 For example, if taking 1500 mg daily, give 1000 mg at Iftar and 500 mg at Suhur. 3

With Sulfonylureas

Reduce sulfonylurea dose by at least 50% or discontinue entirely when combined with semaglutide. 1, 2 Continuing full-dose sulfonylureas with GLP-1 therapy substantially increases severe hypoglycemia risk. 2 This is a common and dangerous pitfall to avoid.

With SGLT2 Inhibitors

SGLT2 inhibitors can be continued unchanged if combined with semaglutide, but only in carefully selected patients. 1 However, patients with history of recurrent dehydration, those living in hot/humid climates with excessive perspiration risk, or those performing intense physical labor should avoid SGLT2 inhibitors during Ramadan. 4

Monitoring Requirements

Self-monitor blood glucose closely during the first 3-4 weeks of Ramadan, particularly in the first few hours after starting the fast and in the late afternoon before breaking fast. 1, 2

Break the fast immediately if blood glucose drops below 70 mg/dL. 1, 2 This is non-negotiable regardless of how well-controlled the patient typically is.

Monitor for dehydration, which can increase thrombotic risk even with semaglutide's favorable profile. 2

Nutritional Guidance

Distribute calories over two to three smaller meals during the non-fasting interval rather than one large meal at sunset. 1, 2 This prevents postprandial hyperglycemia that can occur even with semaglutide.

Break the fast with a small, balanced meal containing fiber, protein, and complex carbohydrates. 1, 2 Avoid rapid eating or overconsumption, which is a common mistake.

Avoid caffeinated or sugary drinks that increase dehydration risk. 2

Maintain adequate hydration by drinking at least 1.5-2 L of water during non-fasting hours. 4

Critical Safety Considerations

The extended label for GLP-1 receptor agonists in cardiovascular and renal protection makes semaglutide particularly valuable for patients with cardiorenal risk factors during Ramadan. 1 This represents a significant advantage over older diabetes medications.

Volume depletion remains a concern even with semaglutide, so adequate hydration during non-fasting periods is essential. 1 The medication itself does not cause dehydration, but the fasting period does.

Post-Ramadan Management

Return the therapeutic regimen to pre-Ramadan schedule after Ramadan ends, and assess overall health, complications, and glycemic control. 1 Most patients on semaglutide will have maintained excellent control throughout Ramadan without requiring any changes.

References

Guideline

SGLT2 Inhibitors During Ramadan Fasting

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Diabetes During Ramadan

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Jardiance During Ramadan

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the recommendations for managing a Muslim patient with type 2 diabetes who is taking a Sodium-Glucose Linked Transporter 2 (SGLT2) inhibitor and plans to fast during Ramadan?
Is Jardiance (Empagliflozin) dose reduction necessary during Ramadan?
How do you use Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide (Victoza) or semaglutide (Ozempic), in diabetic patients during Ramadan?
How should GLP-1 (Glucagon-like peptide-1) receptor agonists, such as liraglutide (Victoza) or semaglutide (Ozempic), be managed in Muslim patients with diabetes who wish to fast during Ramadan?
What is the management approach for a patient experiencing tonic-clonic seizures?
What is the best course of action for a patient with known dilated cardiomyopathy (cardiomyopathy) presenting to the emergency room (ER) with right-sided body weakness and dizziness?
Can a patient with a history of obesity and type 2 diabetes, taking a Glucagon-like peptide-1 (GLP-1) receptor agonist, such as liraglutide (Victoza) or semaglutide (Ozempic), safely take phentermine?
What are the considerations and recommendations for a healthy adult, likely between 40 and 70 years old, with a history of sun exposure and signs of facial aging, seeking a facial lift (rhytidectomy)?
What are the details of Levetiracetam (antiepileptic medication) usage, including dosage and administration guidelines for adults and children?
What is the recommended protocol for urinary alkalinization in a patient undergoing methotrexate (MTX) therapy to reduce the risk of renal toxicity?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.